Ono Pharmaceutical Co (Ono Pharmaceutical Co) Net Income From Continuing Operations : $1,161 Mil (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Ono Pharmaceutical Co's net income from continuing operations for the three months ended in Dec. 2023 was $333 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $1,161 Mil.

Ono Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Ono Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Net Income From Continuing Operations Chart

Ono Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income From Continuing Operations

Get a 7-Day Free Trial

586.09

740.21

928.16

885.71

1,073.82

Ono Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															321.39	143.29	299.79	384.98	333.35

Ono Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,161 Mil.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

OPHLF:USA 4528:Japan ON4:Germany

Address

8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564

Website

http://www.ono.co.jp

Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines

From GuruFocus

Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million

By PRNewswire • 12-01-2023

Samuel Isaly's Eaton Vance Worldwide Health Sciences Fund Q1 Investment Report

By Holly LaFon Holly LaFon • 05-13-2016

Ono Pharmaceutical Co Stock Appears To Be Modestly Undervalued

By GF Value • 07-05-2021

T. Rowe Price Japan Fund Purchases 5 Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-18-2017